Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

SEASONIQUE an extended cycle oral contraceptive

In August 2006 Shire entered into a license agreement in respect of Duramed Pharmaceuticals, Inc's ('Duramed') oral contraceptive, SEASONIQUE. Duramed markets SEASONIQUE in the US. Shire has the rights to market this product in a number of territories outside of North America, including the larger European markets.

On February 24, 2009, Shire and Duramed amended this agreement and it will terminate on December 31, 2009. Pursuant to this amendment, Shire agreed to return to Duramed its rights under the agreement effective February 24, 2009.

Projects in pre-clinical development

A number of projects are underway in the early stages of pre-clinical development for the Specialty Pharmaceuticals area.

Human Genetic Therapies

Treatments for Angioedema

FIRAZYR for hereditary angioedema ('HAE') in the US

FIRAZYR is a treatment for acute HAE which Shire added to the portfolio through its acquisition of a majority voting interest in Jerini during 2008. Jerini received a not approvable letter for FIRAZYR for use in the US from the FDA in April 2008, and met with FDA in December 2008 to discuss the development of FIRAZYR. It was agreed that an additional clinical study would be required before approval could be considered and that a complete response to the not approvable letter would be filed after completion of this study. This additional study will be initiated during the third quarter of 2009.

ERT

Velaglucerase alfa (GA-GCB) - for the treatment of Gaucher disease

Velaglucerase alfa is an enzyme replacement therapy being developed for the treatment of Gaucher disease. Shire has completed enrolment in a worldwide Phase 3 clinical program for velaglucerase alfa. This comprehensive development program includes the evaluation of velaglucerase alfa in nai
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Virginia (PRWEB) June 03, 2015 Photo-Eyewear™ ... changed its name to PogoTec™, Inc. ( http://www.PogoTec.com ... its electronic wearable device products and technologies it is ... creation of three business divisions, PogoTec™ will provide focused ... devices as follows: , , On-Track™ ...
(Date:6/3/2015)... 2015 The National Center for ... record by scaling CD-adapco’s flagship simulation tool STAR-CCM+® ... , STAR-CCM+ is a comprehensive multidisciplinary engineering ... innovation and lower product development costs. CD-adapco joined ... manufacturer Cray to push the code to new ...
(Date:6/3/2015)... June 03, 2015 Global Stem ... Inc. have announced plans to conduct Romania’s first ever ... Through an alliance with Miami-based Stem Cell Training, Inc., ... the Adipose and Bone Marrow Stem Cell Training Course ... reconstructive plastic surgery specialist practicing in Bucharest and Tel ...
(Date:6/3/2015)... June 03, 2015 Intelligent Implant ... of US Patent No. 9,044,273, underpinning the Revolution™ ... thoraco-lumbar spinal fusion implant procedure by eliminating complicated ... one easy-to-use disposable instrument tray. The implants, designed ... benefits over previous technology. Intelligent Implant Systems has ...
Breaking Biology Technology:Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 2NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 3Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 2Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 3Intelligent Implant Systems Announces US Patent Attained for Revolution™ Spinal System 2
... CANNES, France, June 24, 2011 Mediabrands, IPG ... Cannes Lions International Advertising Festival, the results of ... by MIT, Affectiva is able to record and ... points, correlating to an individual,s facial features are ...
... June 24, 2011 Amgen (NASDAQ: AMGN ... for Human Use (CHMP) of the European Medicines Agency ... (panitumumab) be approved for use in the European Union ... second-line in combination with FOLFIRI in patients who have ...
... ,   Coventry Building ... Legion by launching Poppy Online,Saver , a market-leading ... Saver is an ,easy access internet savings account ... each year, with,further withdrawals possible with the loss of ...
Cached Biology Technology:The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 3Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 2Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 3Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 4Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 5Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 6Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 7Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 8Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 9Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 10Coventry Launches Market Leading Online Savings Account With Added Poppy Appeal 2Coventry Launches Market Leading Online Savings Account With Added Poppy Appeal 3
(Date:5/28/2015)... May 28, 2015 Industry analyst firm ... new report titled "Markets for Self-Healing Materials: 2015-2022." According ... capsule and vascular systems, biomaterials, relevant shape memory ... around $2.7 billion by 2020. The ... coverage of smart materials. Other recent n-tech reports have ...
(Date:5/25/2015)... , May 25, 2015  Australia,s market for wearable ... although 2014 saw the advent of several trials and ... April 2015 is expected to ignite interest in wearables ... Australia . This in turn will ... and drive new partnerships amongst vendors and distributors. ...
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4
... highly efficient techniques, Carnegie and Colombian scientists have ... locked in tropical vegetation for 40% of the ... area about four times the size of Switzerland. ... stocks at high spatial resolution over large areas ...
... July 25, 2012 - Migraine can be a disabling ... the acupoint PC6 Neiguan, an approach to controlling nausea ... by published clinical studies in medical literature for the ... May 2012 Neurological Sciences (journal of the ...
... regulated process that occurs in all animals and plants as ... New research published in BioMed Central,s open access journal ... physiological events in the lace plant ( Aponogeton madagascariensis ) ... its leaves. The aquatic lace plant, endemic to ...
Cached Biology News:Forest carbon monitoring breakthrough in Colombia 2Forest carbon monitoring breakthrough in Colombia 3Published clinical trial demonstrates efficacy of Sea-Band® for migraine-related nausea 2Lace plants explain programmed cell death 2